C oncurrent activity of the sympathetic and parasympathetic nervous systems results in complex interactions in the autonomic control of cardiac function.' Several mechanisms may be responsible for these interactions, including local control of the release of the autonomic neurotransmitters, acetylcholine (ACh), and norepinephrine. Evidence has been presented not only for the autoreceptor control of ACh and norepinephrine release from autonomic neurons but also for heteroreceptor control mechanisms. 2 Thus, vagal stimulation or applied ACh have been shown to decrease the release of norepinephrine from sympathetic nerve endings in dog hearts 3 and isolated rabbit atria, 4 respectively. Such a prejunctional mechanism for the control of ACh release by norepinephrine has also been suggested on the basis of in vitro studies of ACh release from isolated guinea pig right atrium 5 and isolated rat right atrium. 6 " 8 The present report supports the hypothesis that there is adrenergic control of ACh release with evidence from an in vivo preparation.
Preliminary reports of some of these results have been presented.
Materials and Methods

Animal Preparation
Male Sprague-Dawley rats (Taconic Farms, Germantown, N.Y.) weighing 220-280 g were used in all experiments. Rats were anesthetized with a combination of 300 mg/kg chloral hydrate (Merck and Co. Inc., West Point, Penn.) and 30 mg/kg sodium pentobarbital (Abbott Laboratories, North Chicago, 111.). Following a midline cervical incision, the trachea was intubated, and the right jugular vein and the left carotid artery were cannulated. Both the right and left vagus nerves were exposed and suspended over stainless steel bipolar electrodes and cut rostral to the electrodes to prevent afferent and efferent vagal reflexes. The electrodes were connected to a stimulus isolation unit (Grass, Quincy, Mass., model S1U5) driven by a Grass (model S88) stimulator. The vagi were given electrical pulse train stimulation: twin 5 volt pulses 25 milliseconds apart and 0.5 milliseconds in duration were administered at a pulse rate (4-5 Hz) chosen to entrain the heart to a rate that was approximately 65-70% of the control (prestimulation) rate. With pulse train stimulation in this range of frequencies, sinoatrial nodal rhythm synchronized with the periodic bursts of vagal activity," 12 allowing reproduction of the desired percent decrease in heart rate for each animal regardless of exact individual resting rate.
Blood pressure was monitored from the carotid artery cannula through a pressure transducer (Statham model P23AC, Hato Rey, Puerto Rico) and recorded throughout the experiment on a Grass (model 7D) polygraph. A lead II surface electrocardiogram was recorded continuously on the Grass polygraph, and heart rate was determined from the interval between successive P waves.
Drug Protocols
The a,-selective agonist phenylephrine (PE) and the a 2 -selective agonist BHT-920 were tested for their effect on heart rate and blood pressure when administered alone or during bilateral vagus nerve stimulation. Vagal stimulation was initiated 1 minute before the i.v. injection of agonist. PE was administered at several dose levels from 1-100 /ng/kg, and BHT-920 was given in doses of 10 and 100 fig/kg . Three or four trials of vagal stimulation alone, agonist alone, and the combined treatments were made on each animal with a washout (recovery) period of at least 5 minutes between treatments.
The effects of PE on heart rate and blood pressure were challenged with the a,-selective antagonist prazosin and the a 2 -selective antagonists yohimbine and rauwolscine. The antagonists were administered 2 minutes before the initiation of vagal stimulation (thus, 3 minutes before the injection of PE).
In some animals, bradycardia was produced by administration of the muscarinic agonist bethanechol (2.5 mg/kg, i.p.) in place of vagal stimulation. In another group of animals, blood pressure was increased by the temporary occlusion of the abdominal aorta in place of PE administration.
Drugs
BHT-920 was generously provided by Boehringer Ingelheim KG (Ingelheim am Rhein, Germany), prazosin HC1 was the kind gift of Pfizer Inc. (Groton, Conn.), and phenylephrine HC1 (PE) was provided by Winthrop Labs (New York, N.Y.). Yohimbine HC1 was purchased from Sigma (St. Louis, Mo.), rauwolscine HC1 from Atomergic Chemetals (Plainview, N.Y.), and bethanechol chloride from Merck Sharp & Dohme (West Point, Penn.). All drugs were dissolved in physiologic saline solution except prazosin HC1, which was dissolved in dimethylsulfoxide and diluted with saline to a final concentration of dimethylsulfoxide not greater than 10%; this vehicle solution had no effect on the measured properties. All drugs were administered by i.v. injection unless otherwise noted.
Calculations and Statistics
Heart rate and mean arterial blood pressure were determined during the following treatment periods: 1) control conditions, 2) agonist administration alone, 3) vagal stimulation alone, and 4) agonist administration during vagal stimulation (these periods were repeated in the case of pretreatment with antagonist). The values from 3 or 4 trials of each treatment period were averaged for each animal. The data reported here are the maximal treatment-induced changes from control values, which were seen at 10 seconds after agonist administration for blood pressure (mm Hg, mean ± SEM) and at 60 seconds for heart rate (bpm, mean ± SEM). Where appropriate, blood pressure and heart rate data from each treatment group were compared by two-way analysis of variance (ANOVA) and orthogonal comparisons.
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Results
The resting heart rate for the rats in these studies was 433 ± 5 beats per minute. This rate is elevated compared to that in control rats because cutting the cervical vagus nerves releases the heart from central parasympathetic control. Electric stimulation of the vagus nerves was adjusted to effect a 35-40% decrease in heart rate (a decrease of 150-170 bpm). This bradycardia was maintained for 150 seconds, the entire period of vagal stimulation. A slight decrease in blood pressure accompanied the bradycardia. Figure 1 shows the effects of vagal stimulation on heart rate (lower panel) and blood pressure (upper panel). Also shown in Figure 1 are the heart rate and blood pressure responses to the a,-selective agonist PE. Note that since afferent and efferent vagal fibers were severed, reflex responses to vagal stimulation or PE injection were not observed for blood pressure or heart rate, respectively. When injected alone, PE (25 Mg/kg) increased blood pressure dramatically, from 80 to 148 mm Hg, but had no effect on heart rate. However, when PE was administered during vagal stimulation, not only did blood pressure increase, but there was also a significant attenuation of the vagally induced bradycardia (the maximum increase in heart rate being 47 bpm). This observation is consistent with the hypothesis that activation of a-receptors decreases the release of ACh from parasympathetic neurons. The maximum increase in blood pressure occurred at 10 seconds after PE administration, and the maximum change in heart ! -so- rate was observed at 60 seconds. ANOVA treatment of the heart rate data from 45-150 seconds in Figure 1 indicated that the heart rate resulting from PE administration during vagal stimulation was significantly higher than from vagal stimulation alone (p<0.05, F [1, 50] = 6.94). The effect of PE to increase blood pressure was also highly significant (p<<0.001, F [1,50]= 176).
Both blood pressure and heart rate responses to PE were dose dependent, as shown in Figure 2 . Curves were fitted by eye to the data points, which represent the changes in blood pressure (upper panel) and heart rate (lower panel) with increasing doses of PE during vagal stimulation. The blood pressure changes were plotted for 10 seconds post-PE injection, and the heart rate changes were plotted for 60 seconds post-PEthe maximum response times for each (see Figure 1) . The ED 50 for the increase in blood pressure was 8 /xg/kg, and the ED 50 for the increase in heart rate was 19 Mg/kgSeveral a-antagonists were used to characterize the heart rate and blood pressure effects of PE during stimulation of the vagus nerves. Figure 3 shows the results of treatment with prazosin, an a,-selective antagonist, and rauwolscine, an a 2 -selective antagonist. When injected alone, 50 £tg/kg of prazosin had little effect on heart rate but decreased blood pressure as expected. Initiation ofvagal stimulation in the presence of prazosin still produced a bradycardia. However, injection of PE subsequent to prazosin resulted in no change in blood pressure or heart rate. Rauwolscine injected alone (50 /Ag/kg) had no effect on heart rate and caused little decrease in blood pressure. Vagal stimulation following rauwolscine administration resulted in the characteristic pronounced decrease in heart rate and a small decrease in blood pressure. Injection of PE subsequent to rauwolscine resulted in an increase in blood pressure and a marked attenuation of the vagal bradycardia, as seen in the absence of antagonist. The observation that the ability of PE to raise blood pressure and to attenuate vagal bradycardia is blocked by prazosin, but not by rauwolscine, suggests that both responses are mediated through a,-adrenergic receptors.
The heart rate data in Figure 3 , following PE injection, were compared by ANOVA and orthogonal comparisons. The heart rate changes induced by PE with prazosin during vagal stimulation were not different from those induced by vagal stimulation alone (p -0.05). Further, PE with rauwolscine during vagal stimulation had the same effect on heart rate as did PE during vagal stimulation (/? -0.05).
The dose-response relations for prazosin, rauwolscine, and another a 2 -selective antagonist, yohimbine, are compared in Figure 4 (curves were fitted to the data points by eye). At low doses (50-100 /i.g/kg), yohimbine and rauwolscine had no pronounced effect on heart rate or blood pressure and did not block the effects of PE during vagal stimulation. At much higher doses (1-2 mg/kg), these antagonists produced decreases in both heart rate and blood pressure and decreased the effects of PE on blood pressure and vagal bradycardia, as shown in Figure 4 . Prazosin (ID 50 = 0.8 /u.g/kg), however, was about 1,000 times more potent than yohimbine (ID 50 = 600 /Ag/kg) or rauwolscine (ID 50 = 1,300 ^ig/kg) in inhibiting the heart rate response to PE during vagal stimulation at a dose of 5 /Ag/kg. Prazosin (ID 50 =1.2 /ng/kg) was also considerably more potent than yohimbine (ID 50 = 220 /*.g/kg) or rauwolscine (ID 50 = 1,500 /u.g/kg) in blocking the effect of PE on blood pressure.
FIGURE 4. Log dose-response curve for antagonist inhibition of the effects of PE on heart rate and blood pressure during vagal stimulation (4-6 animals/point).
The role of an a,-adrenergic receptor in mediating the effect of PE on vagal bradycardia was further supported by studies with the a 2 -selective agonist BHT-920. In contrast to the effect of PE, BHT-920 did not attenuate the bradycardia resulting from vagal stimulation. Figure 5 shows that when BHT-920 was injected alone, it increased blood pressure (upper panel) and decreased heart rate only slightly (lower panel). When administered during stimulation of the vagus nerves, BHT-920 caused a slight increase in blood pressure but did not increase heart rate.
Statistical analysis of the blood pressure data in Figure 5 revealed that blood pressure was significantly higher with BHT-920 alone (p<<0.001) or with BHT-920 treatment during vagal stimulation (p< 0.05) when compared to vagal stimulation alone. This finding supports the argument that a 2 -adrenoceptors are present in vascular smooth muscle where they mediate vasoconstriction.
14 Analysis of the heart rate data in Figure 5 indicated no significant difference between treatment with BHT-920 during vagal stimulation and vagal stimulation alone (p>0.05).
In some animals,the same degree of bradycardia that resulted from electric stimulation of the vagus nerves was produced and sustained by administration of the muscarinic agonist bethanechol (2.5 mg/kg i.p.). When PE was injected during bethanechol induced bradycardia, no significant change in heart rate was seen (Table 1) . In another experiment, the abdominal aorta was temporarily clamped to produce a sharp rise in blood pressure comparable to that resulting from PE administration. When this maneuver was performed during vagally induced bradycardia no further change in heart rate was seen (Table 1) .
Discussion
In the studies presented here, blood pressure and heart rate were monitored from rats that received electrical stimulation of vagus nerves, drug injections, or both. Pulse train electric stimulation of the cardiac ends of the transected right and left vagus nerves resulted in a maintained bradycardia (Figure 1 ). The injection of PE alone caused an increase in blood pressure with no change in heart rate ( Figure 1) . However, when PE was injected during vagal stimulation, not only was the expected increase in blood pressure observed but also an increase in heart rate ( Figure 1) .
The increases in heart rate and blood pressure resulting from PE administration during vagal stimulation •Protocol similar to that used in Figure 1 .
•(Treatment A was ongoing for 1 minute (vagal stimulation) or 5 minutes (bethanechol injection, 2.5 mg/kg i.p.) before initiation of treatment B (injection of PE, 25 |ig/kg i. v.; or clamping of abdominal aorta). Change in blood pressure and heart rate from pretreatment (control) value was recorded for treatment A prior to initiation of treatment B, and again at 10 seconds after treatment B for blood pressure and 60 seconds after treatment B for heart rate (means ± SEM).
JThese data are from Figure 1 . §p<0.05 when A value compared to B value with Student's t test.
both occurred over the same dosage range, as shown in Figure 2 . To rule out the possibility that the increase in heart rate was secondary to the effect of PE to increase blood pressure, an additional experiment was performed in which the abdominal aorta was temporarily clamped to produce a sharp rise in blood pressure comparable to that resulting from PE administration. When this maneuver was performed during vagally mediated bradycardia, no change in heart rate was seen (Table  1) . We also considered the possibility that the effect of PE was a rate related event, attributed to the decrease in heart rate resulting from vagal stimulation. To test this, the same degree of bradycardia that resulted from electric stimulation of the vagus nerves was produced by administration of the muscarinic agonist bethanechol. When PE was injected during bethanechol induced bradycardia, there was no significant change in heart rate (Table 1) . Thus, the increase in heart rate caused by PE administration during vagal stimulation does not appear to be a pressure-or rate-related phenomenon. The bethanechol experiment also affords strong evidence for a prejunctional rather than a postjunctional site for the a mechanism described here. If the a-receptor stimulated increase in heart rate was mediated through a postjunctional adrenoceptor, PE should be equally effective at increasing heart rate when administered during vagally induced bradycardia (ACh as the muscarinic agonist) or during bethanechol induced bradycardia. Since PE had no effect on heart rate in the presence of bethanechol, a prejunctional mechanism, inhibition of ACh release is supported.
That the prejunctional a-adrenergic receptor studied here is of the a,-subtype is suggested by the differential effects of the a,-selective agonist PE and the a 2 -selective agonist BHT-920 on heart rate during vagal stimulation (Figures 1 and 5 ). An a, assignment is further supported by studies with specific a-adrenoceptor antagonists. The effects of PE on heart rate and blood pressure during vagal stimulation were uniquely blocked by the a,-antagonist prazosin over a dosage range consistent with other characterizations of aadrenoceptor binding or physiology.' 516 In contrast, blockade by the a 2 -antagonists yohimbine and rauwolscine was evident only in much higher doses ( Figures 3  and 4) , well above those generally needed for a 2 -blockade. The similarity between the antagonist doseresponse curves shown here for in vivo heart rate ( Figure 4) and that of Wetzel et al 8 and McDonough et al 6 for in vitro ACh release is strong evidence that both parameters are regulated through the same (a,-adrenergic) receptor. The positive chronotropic and positive inotropic effects of catecholamines in the heart are largely mediated by /3-adrenergic receptors. There is some evidence that a-adrenergic receptors may contribute to the positive inotropic response to sympathetic activity, 1718 but a direct role for a-adrenergic receptors in mediating chronotropic responses is unlikely.
l9 Our data are consistent with this latter point; no changes in heart rate were seen in our preparation with the administration of either the a-agonist PE (Figure 1 ) or with the administration of a-antagonists (Figure 3) .
A number of studies suggest that prejunctional aadenergic receptors do serve an important role in controlling the release of norepinephrine from sympathetic nerve endings in the heart. 520 Starke 5 reported that several a-agonists decreased, while a-antagonists increased, the outflow of norepinephrine from isolated rabbit hearts subjected to electric sympathetic nerve stimulation. That this prejunctional a-adrenergic inhibitory feedback mechanism is subserved by a 2 -adrenergic receptors is supported by much evidence and has been reviewed. 21 However, several studies suggest that prejunctional receptors subtyped as a,-adrenergic may also play a role in this function. Prejunctional a-adrenoceptor activity was determined by Kobinger and Pichler 20 by monitoring changes in tachycardia elicited by electric stimulation of spinal sympathetic roots in the pithed rat preparation. This tachycardia was inhibited by several agonists (including the a |-selective agonist methoxamine), an effect that was selectively blocked by prazosin. Quantitative comparison of their agonist and antagonist data suggests that most of the adrenoreceptors at this site are of the a 2 -subtype but supports the existence of a popula-
